Emerging Therapies for Nonalcoholic Fatty Liver Disease

被引：11

作者：

Hameed, Bilal ^{[1
]}

Terrault, Norah ^{[1
]}

机构：

[1] Univ Calif San Francisco, Div Gastroenterol, S357,513 Parnassus Ave, San Francisco, CA 94143 USA

来源：

CLINICS IN LIVER DISEASE | 2016年 / 20卷 / 02期

关键词：

Nonalcoholic fatty liver disease; FXR agonists; Insulin sensitizers; PPAR agonists; Antifibrotic agents; FARNESOID-X-RECEPTOR; TISSUE INSULIN-RESISTANCE; LYSYL OXIDASE; REMOGLIFLOZIN ETABONATE; OBETICHOLIC ACID; NUCLEAR RECEPTOR; ADIPOSE-TISSUE; HEPATIC STEATOSIS; HUMAN HEPATOCYTES; GLYCEMIC CONTROL;

D O I：

10.1016/j.cld.2015.10.015

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Nonalcoholic fatty liver disease is the most common cause of liver disease in the United States. There are no drug therapies approved for the treatment of nonalcoholic steatohepatitis (NASH). Multiple different pathways are involved in the pathogenesis and each can be the target of the therapy. It is possible that more than 1 target is involved in disease development and progression. Multiple clinical trials with promising agents are underway. Because NASH is a slowly progressive disease and treatment likely to be of prolonged duration, acceptance and approval of any agent will require information on long-term clinical benefits and safety.

引用

页码：365 / +

页数：22

共 98 条

[1]

ANSHER SS, 1983, HEPATOLOGY, V3, P932

[2] Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program [J].

Armstrong, M. J. ;

Houlihan, D. D. ;

Rowe, I. A. ;

Clausen, W. H. O. ;

Elbrond, B. ;

Gough, S. C. L. ;

Tomlinson, J. W. ;

Newsome, P. N. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) :234-242

[3] Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes [J].

Aubert, R. E. ;

Herrera, V. ;

Chen, W. ;

Haffner, S. M. ;

Pendergrass, M. .

DIABETES OBESITY & METABOLISM, 2010, 12 (08) :716-721

[4] PPARδ:: a dagger in the heart of the metabolic syndrome [J].

Barish, GD ;

Narkar, VA ;

Evans, RM .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) :590-597

[5] The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis [J].

Barreyro, Fernando J. ;

Holod, Silvia ;

Finocchietto, Paola V. ;

Camino, Alejandra M. ;

Aquino, Jorge B. ;

Avagnina, Alejandra ;

Carreras, Maria C. ;

Poderoso, Juan J. ;

Gores, Gregory J. .

LIVER INTERNATIONAL, 2015, 35 (03) :953-966

[6] Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment [J].

Barry-Hamilton, Vivian ;

Spangler, Rhyannon ;

Marshall, Derek ;

McCauley, Scott ;

Rodriguez, Hector M. ;

Oyasu, Miho ;

Mikels, Amanda ;

Vaysberg, Maria ;

Ghermazien, Haben ;

Wai, Carol ;

Garcia, Carlos A. ;

Velayo, Arleene C. ;

Jorgensen, Brett ;

Biermann, Donna ;

Tsai, Daniel ;

Green, Jennifer ;

Zaffryar-Eilot, Shelly ;

Holzer, Alison ;

Ogg, Scott ;

Thai, Dung ;

Neufeld, Gera ;

Van Vlasselaer, Peter ;

Smith, Victoria .

NATURE MEDICINE, 2010, 16 (09) :1009-U107

[7] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].

Belfort, Renata ;

Harrison, Stephen A. ;

Brown, Kenneth ;

Darland, Celia ;

Finch, Joan ;

Hardies, Jean ;

Balas, Bogdan ;

Gastaldelli, Amalia ;

Tio, Fermin ;

Pulcini, Joseph ;

Berria, Rachele ;

Ma, Jennie Z. ;

Dwivedi, Sunil ;

Havranek, Russell ;

Fincke, Chris ;

DeFronzo, Ralph ;

Bannayan, George A. ;

Schenker, Steven ;

Cusi, Kenneth .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307

[8] Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease [J].

Bernsmeier, Christine ;

Meyer-Gerspach, Anne C. ;

Blaser, Lea S. ;

Jeker, Lia ;

Steinert, Robert E. ;

Heim, Markus H. ;

Beglinger, Christoph .

PLOS ONE, 2014, 9 (01)

[9] Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis [J].

Boettcher, E. ;

Csako, G. ;

Pucino, F. ;

Wesley, R. ;

Loomba, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (01) :66-75

[10] Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player [J].

Bojic, Lazar A. ;

Huff, Murray W. .

CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (02) :171-177

← 1 2 3 4 5 6 7 8 9 10 →